{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:44:40Z","timestamp":1790203480845,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":692,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2000,2]]},"abstract":"<jats:p>Between January 1992 and January 1999, we treated 378 B\u2010chronic lymphocytic leukaemia (CLL) patients with cladribine (2\u2010CdA), and 255 of the patients were also treated with prednisone. A total of 194 patients were previously untreated, and 184 had relapsed or refractory disease after previous other therapy. Complete response (CR) was obtained in 111 (29.4%) and partial response (PR) in 138 (36.5%) patients, giving an overall response (OR) rate of 65.9%. CR and OR were achieved more frequently in patients in whom 2\u2010CdA was a first\u2010line treatment (45.4% and 82.5% respectively) than in the pretreated group (12.5% and 48.4% respectively) (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). The median duration of OR for previously untreated patients was 14.7 months and for pretreated patients 13.5 months (<jats:italic>P<\/jats:italic>\u2003=\u20030.09). The median survival evaluated from the beginning of 2\u2010CdA treatment was shorter in the pretreated group (16.3 months) than in the untreated group (19.4 months) (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). A total of 117 (63.9%) patients died in the pretreated group and 63 (32.6%) in the untreated group. In pretreated patients, 2\u2010CdA\u2003+\u2003prednisone (P) and 2\u2010CdA alone resulted in similar OR (51.0% and 45.0% respectively; <jats:italic>P<\/jats:italic>\u2003=\u20030.4). In contrast, in untreated patients, 2\u2010CdA\u2003+\u2003P produced a higher OR (85.4%) than 2\u2010CdA alone (72.1%) (<jats:italic>P<\/jats:italic>\u2003=\u20030.04). Infections and fever of unknown origin, observed in 91 (49.4%) pretreated and 74 (38.1%) untreated patients (<jats:italic>P<\/jats:italic>\u2003=\u20030.03), were the most frequent toxic effects. Our results indicate that 2\u2010CdA is an effective, relatively well\u2010tolerated drug, especially in previously untreated CLL.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2000.01850.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:21:45Z","timestamp":1047363705000},"page":"357-368","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Cladribine with or without prednisone in the treatment of previously treated and untreated B\u2010cell chronic lymphocytic leukaemia \u2014 updated results of the multicentre study of 378 patients"],"prefix":"10.1111","volume":"108","author":[{"family":"Robak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"B\u0142o\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kasznicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Konopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ceglarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dmoszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Soroka\u2010Wojtaszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Skotnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dwilewicz\u2010Trojaczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tomaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kuliczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Potoczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Zdziarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hansz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ho\u0142owiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Grieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-6-466"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-7-199810010-00010"},{"key":"e_1_2_6_4_2","first-page":"534","article-title":"Present status of purine analogs in the therapy of chronic lymphocytic leukemias","volume":"11","author":"Bergman I.","year":"1997","journal-title":"Leukemia"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1998.16.3.850","article-title":"Fewer infection but maintained antitumor activity with lower\u2010dose versus standard\u2010dose cladribine in pretreated low grade non\u2010Hodgkin's lymphoma","volume":"16","author":"Betticher D.C.","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80180-5"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.9922637.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30177-1"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07674.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00368-1"},{"key":"e_1_2_6_11_2","first-page":"14","article-title":"Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation","volume":"35","author":"Cheson B.D.","year":"1998","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson B.D.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830290307"},{"key":"e_1_2_6_14_2","first-page":"1132","article-title":"2\u2010Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL)","volume":"9","author":"Delannoy A.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309054731"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196904)23:4<900::AID-CNCR2820230427>3.0.CO;2-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197303)31:3<502::AID-CNCR2820310303>3.0.CO;2-7"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709039038"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19970601)79:11<2107::aid-cncr7>3.0.co;2-l"},{"key":"e_1_2_6_20_2","first-page":"1432","article-title":"Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced\u2010stage chronic lymphocytic leukaemia","volume":"377","author":"Johnson S.","year":"1996","journal-title":"Lancet"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.679"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210083271504"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409051654"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010604"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00333a046"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.19.bloodjournal74119"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2878.2878"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(93)90003-M"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V85.2.307.307","article-title":"Advances in the biology and treatment of B\u2010cell chronic lymphocytic leukemia","volume":"85","author":"O'brien S.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400816"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood.V82.6.1695.1695","article-title":"Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis \u2014 derived prognostic model for response to treatment","volume":"82","author":"O'brien S.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402033300504"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V72.3.1069.bloodjournal7231069","article-title":"2\u2010Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia","volume":"72","author":"Piro L.D.","year":"1989","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_37_2","first-page":"141","article-title":"A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG\/NCI\u20106 and EGOG inter\u2010group study (abstract)","volume":"88","author":"Rai K.R.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"issue":"1","key":"e_1_2_6_39_2","first-page":"190a","article-title":"Randomized multicenter study of the effectiveness of 2\u2010chlorodeoxyadenosine with prednisone versus chlorambucil with prednisone in previously untreated chronic lymphocytic leukemia (CLL)","volume":"92","author":"Robak T.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(97)00349-3"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1997.tb00933.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051736"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.29.29"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.570"},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood.V50.6.1049.1049","article-title":"Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia","volume":"50","author":"Sawitsky A.","year":"1977","journal-title":"Blood"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.458"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01935.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.01850.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2000.01850.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2000.01850.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T08:21:27Z","timestamp":1698567687000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2000.01850.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["10.1046\/j.1365-2141.2000.01850.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2000.01850.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]},"assertion":[{"value":"2001-12-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}